News

The Notice of Allowance is for U.S. Patent Application No. 14/230,067, "Methods for Treatment of Attention Deficit Hyperactivity Disorder", which relates to HLD-200, including its unique pharmacokinetic profile.

This award enables Integral Molecular to understand how human antibodies protect (or fail to protect) against these viruses. Using its proprietary Shotgun Mutagenesis Epitope Mapping technology, Integral Molecular

MEDI2452 is being developed by MedImmune, AstraZeneca’s biologics research and development arm. Updates on BRILINTA development programme and data from cardiovascular portfolio to be presented at American Heart

"RMD’s world-class research continues to be on the cutting edge of new technologies," said Peter Sulick, Dynasil’s Chairman of the Board, Chief Executive Officer and President. "RMD is

Through this collaboration of organizations from the public and private sectors, Sayana Press will be sold for US $1 per dose to qualified purchasers, who can help enable

Symptoms of schizoaffective disorder are complex and without treatment they are disabling. Janssen Scientific Affairs director of Clinical Development Dong-Jing Fu said: "Schizoaffective disorder is a difficult-to-treat disease.

SSc is a rare multisystem, autoimmune disease that results in the overproduction and abnormal growth of collagen, which causes fibrosis of the skin and internal organs. dcSSc is

The company is focused on the development and commercialization of a once-daily, oral medication to treat liver diseases and cholesterol gallstones. The single center, randomized, double blind, placebo

The company said that the new delivery approaches seek to target the desired tissue more effectively. The deal builds on an existing collaboration between the two firms, and